STK11 and neoplasm: Previous studies have also suggested that some genetic alterations in the tumor cells, such as somatic mutations in serine/threonine kinase 11 (STK11) or in kelch-like ECH-associated protein 1 (KEAP1), could serve as biomarkers to predict responses to ICIs in NSCLC [20,21].